New combo therapy aims to shrink melanoma before surgery

NCT ID NCT04139902

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 17 times

Summary

This study tests whether giving immunotherapy drugs before surgery can shrink advanced melanoma (stage III or IV) that can be removed. About 48 adults will receive either one drug (dostarlimab) or two drugs (dostarlimab plus cobolimab) before their operation. The main goal is to see how many patients have most of their tumor killed by the treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Georgetown University Medical Center

    Washington D.C., District of Columbia, 20007, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • UPMC Hillman Cancer Center Washington

    Washington, Pennsylvania, 15301, United States

Conditions

Explore the condition pages connected to this study.